Astonea Labs Limited promoter Ashish Gulati acquired 14,000 equity shares through open market transactions on September 15 and 16, 2026. The purchase increased his stake in the company to 70.94%.

The acquisition was made voluntarily under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Although the transaction did not trigger the mandatory disclosure threshold, the filing was submitted to ensure transparency regarding the promoter's shareholding.

Shareholding Details

Prior to the acquisition, Ashish Gulati held 74,42,970 shares, representing 70.81% of the total voting capital. The addition of 14,000 shares, which accounts for 0.13% of the capital, brought his total holding to 74,56,970 shares.

The total equity share capital of Astonea Labs Limited remained unchanged at 1,05,11,000 equity shares following the transaction. No encumbrances or pledges were reported against these specific shares in the disclosure.

Transaction Breakdown

The disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, details eight separate trades executed on the Bombay Stock Exchange. The transactions were spread across two days, with one trade on September 15 and seven on September 16.

The average price per share varied slightly across the trades, ranging from ₹285 to ₹313. The total value of the acquisition was ₹36,57,000.

Astonea Labs Limited’s Board of Directors approved the appointment of Chander Shekhar as internal auditor for FY27 on September 9, 2026. The meeting also covered cost audit reports, a new subsidiary, and overseas investment.

The Board considered and took on record the Cost Audit Report for FY26 received from Mukesh Kumar Gupta of M/s. Balwinder & Associates. The report contained no adverse remarks or qualifications.

Internal Auditor Appointment

Chander Shekhar, a Chartered Accountant with Membership No. 506340 and Firm Registration No. 020828N, was appointed pursuant to Section 138 of the Companies Act, 2013. He is not related to any director or key managerial personnel.

Subsidiary Incorporation

The Board approved the incorporation of Longevity Science Private Limited as a wholly owned subsidiary, holding at least 51% voting power. A name correction application is pending for an erroneous submission to the Registrar of Companies.

Overseas Direct Investment

Astonea Labs approved an initial capital investment of up to $10,000 in Astonea LLC, its wholly owned US subsidiary in Wyoming. The investment complies with FEMA and ODI regulations.

Agreement Termination

The Board confirmed the immediate termination of material supply and distribution agreements with Astonea One Private Limited, superseding a previous deferral decision.